RT Journal Article
SR Electronic
T1 Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.07.21263206
DO 10.1101/2021.09.07.21263206
A1 Bergman, Peter
A1 Blennow, Ola
A1 Hansson, Lotta
A1 Mielke, Stephan
A1 Nowak, Piotr
A1 Chen, Puran
A1 Söderdahl, Gunnar
A1 Österborg, Anders
A1 Edvard Smith, C. I.
A1 Wullimann, David
A1 Vesterbacka, Jan
A1 Lindgren, Gustaf
A1 Blixt, Lisa
A1 Friman, Gustav
A1 Wahren-Borgström, Emilie
A1 Nordlander, Anna
A1 Gomez, Angelica Cuapio
A1 Akber, Mira
A1 Valentini, Davide
A1 Norlin, Anna-Carin
A1 Thalme, Anders
A1 Bogdanovic, Gordana
A1 Muschiol, Sandra
A1 Nilsson, Peter
A1 Hober, Sophia
A1 Loré, Karin
A1 Chen, Margaret Sällberg
A1 Buggert, Marcus
A1 Ljunggren, Hans-Gustaf
A1 Ljungman, Per
A1 Aleman, Soo
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.07.21263206.abstract
AB Background Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate the safety and efficacy after two doses of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls.Methods 539 study subjects (449 patients and 90 controls) were included in the clinical trial. The patients had either primary (n=90), or secondary immunodeficiency disorders due to human immunodeficiency virus infection (n=90), allogeneic hematopoietic stem cell transplantation/chimeric antigen receptor T cell therapy (n=90), solid organ transplantation (SOT) (n=89), or chronic lymphocytic leukemia (CLL) (n=90). The primary endpoint was seroconversion rate two weeks after the second dose. The secondary endpoints were safety and documented SARS-CoV-2 infection.Findings Adverse events were generally mild, but one case of fatal suspected unexpected serious adverse reaction occurred. 72·2% of the immunocompromised patients seroconverted compared to 100% of the controls (p=0.004). Lowest seroconversion rates were found in the SOT (43·4%) and CLL (63·3%) patient groups with observed negative impact of treatment with mycophenolate mofetil and ibrutinib, respectively.Interpretation The results showed that the mRNA BNT162b2 vaccine was safe in immunocompromised patients. The rate of seroconversion was substantially lower than in healthy controls, with a wide range of rates and antibody titres among predefined patient groups and subgroups. This clinical trial highlights the need for additional vaccine doses in certain immunocompromised patient groups and/or subgroups to improve immunity.Funding Knut and Alice Wallenberg Foundation, Nordstjernan AB, Region Stockholm, Swedish Research Council, Karolinska Institutet, and organizations for PID/CLL-patients in Sweden.Competing Interest StatementDeclaration of interests SM received honoraria via his institution from Celgene/BMS, Novartis, Gilead/Kite, DNA Prime for lectures and educational events and as a member and/or head of data safety monitoring boards from Miltenyi and Immunicum outside the submitted work. SH has been taking part in a COVID-19 Strategic Consultancy Group and a Virtual Advisory Board, not related to the current study. KL reports grants from Knut and Alice Wallenberg Foundation for this study. HGL reports grants from Knut and Alice Wallenberg Foundation and Nordstjernan AB for studies on COVID-19, and has served on the UK-CIC Oversight Committee, is leading the Karolinska Institutet COVID-19 vaccine group, and has served on several Karolinska Institutet COVID-19 Task force and Reference groups. PL reports grants from Pfizer, grants from MSD, grants and personal fees from Takeda, personal fees from AiCuris, personal fees from OctaPharma, outside the submitted work. SA has received honoraria for lectures and educational events, not related to this work, from Gilead, AbbVie, MSD, Biogen and Netdoktor, and reports grants from Knut and Alice Wallenberg Foundation for this study.Clinical Trialclinicaltrials.gov (no. 2021-000175-37).Funding StatementThis study has been funded by the Knut and Alice Wallenberg Foundation, Nordstjernan AB, Region Stockholm (Clinical research position-, ALF-, and CIMED-grants), the Swedish Research Council, a graduate student fellowship from Karolinska Institutet. In addition, the Swedish patient organizations of Primary Immunodeficiencies (PIO) and Hematology (Swedish Blood Cancer Foundation) provided grants. Neither of funders had any role in study design, collection, analysis, interpretation of data or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Medical Product Agency (ID 5.1-2021-5881) and the Swedish Ethical Review Authority (ID 2021-00451). All participants provided written informed consent. This trial was registered at EudraCT (no. 2021-000175-37) and clinicaltrials.gov (no. 2021-000175-37).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing Data will be submitted to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT). The full clinical study protocol is available via the SciLifeLab Data Repository (English version: doi:10.17044/scilifelab.15059364; Swedish version doi: 10.17044/scilifelab.15059355). Anonymous data displayed in the manuscript will be made available upon request to the corresponding author following publication of the present article. Data will be made available in a form not deviating from what is accepted by local regulatory authorities with respect to handling of patient data, and in adherence of the policies of the Karolinska University Hospital and Karolinska Institutet.